Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WT1-TCR T Cells in NSCLC and Mesothelioma
NCT02408016Phase 2Terminated
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- May 2015
- Primary completion
- Jun 2020
- Modality
- Gene Editing, Gene Silencing, TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of JTCR016 in non-small cell lung cancer (NSCLC), mesothelioma, sponsored by Fred Hutchinson Cancer Center. Started May 2015; status: terminated.
02
Drugs
JTCR016
03
Conditions
non-small cell lung cancer (NSCLC)mesothelioma
Beyond the preview
Go deeper on NCT02408016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02408016.